Clinical Trials Logo

Post Partum Hemorrhage clinical trials

View clinical trials related to Post Partum Hemorrhage.

Filter by:

NCT ID: NCT03707132 Completed - Placenta Accreta Clinical Trials

Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta

Start date: October 1, 2014
Phase:
Study type: Observational

Monocentric prospective observational study comparing the use of tourniquet in low uterus segement versus standard procedure in hysterectomy owing to placenta accreta

NCT ID: NCT03693599 Not yet recruiting - Clinical trials for Post Partum Hemorrhage

Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section

NCT ID: NCT03680339 Not yet recruiting - Clinical trials for Post Partum Hemorrhage

The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS

Start date: September 2018
Phase: Phase 4
Study type: Interventional

• Patients will be divided into two groups 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen Then we will compare between two groups regarding - Intaoperative blood loss - Risk of Postpartum hemorraghe in the first 24 hrs - HB pre and postoperative for all patients Intraoperative blood loss will be estimated by the number and weight of soaked towels and amount of blood in suction unit

NCT ID: NCT03592303 Not yet recruiting - Clinical trials for Post Partum Hemorrhage

Bedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S)

HPPTEG6S
Start date: August 2018
Phase:
Study type: Observational

Postpartum hemorrhage (PPH) is one of the leading causes of maternal deaths. Its prognosis is directly influenced by the early diagnosis and treatment of the associated coagulopathy. In this context, fibrinogen concentration is the best predictor of a severe PPH. The medical interest of thromboelastography/elastometry to early detect and guide the rapid correction of coagulopathy in PPH is regularly discussed. The principal aim of this study is to evaluate the performance of a new hemostasis point of care device (thromboelastography - TEG ®6S) for the diagnosis of coagulopathy during PPH. A secondary aim will be to determine the normal values of TEG6S at the end of a normal pregnancy.

NCT ID: NCT03591679 Completed - Clinical trials for Post Partum Hemorrhage

Bilateral Uterine Artery Ligation in Reducing Incidence of Postpartum Hemorrhage in Cesarean Section

Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

The patients were recruited from women attending labor ward to undergo cesarean section.

NCT ID: NCT03570723 Recruiting - Placenta Previa Clinical Trials

Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

Objective: To investigate the effect of A glove-loaded Foley's catheter tamponade versus stepwise uterine devascularization on blood loss during cesarean section (CS) in patients with complete placenta previa.

NCT ID: NCT03565276 Not yet recruiting - Clinical trials for Post Partum Hemorrhage

Tranexamic Acid for Prevention of Postpartum Haemorrhage: a Dose-finding Study

Start date: July 2018
Phase: Phase 3
Study type: Interventional

Published trials on tranexamic acid (TxA) for prevention have used a variety of fixed (0.5gm or 1gm) and body-weight adjusted (10mg/kg or 15mg/kg) doses of TxA. Given the wide range of bodyweights of pregnant women in contemporary obstetric practice, it is critical to determine the minimum effective dose of TxA, so as to avoid under- or over-dosing. The rationale of this study is to determine the minimum effective dose of TxA that is required to attain therapeutic plasma levels of TxA, established at 5-15mg/L, following administration of a single dose of intravenous (IV) TxA after childbirth and the clamping the umbilical cord, and before delivery of the placenta. Following birth of the infant, and upon clamping the umbilical cord, the investigators will administer a single dose of IV TxA in 100ml of 0.9% sodium chloride at 50mg/min according to the dose-escalation schedule described below. The slow rate of infusion has been chosen to prevent untoward effects such as hypotension that have been noted when the rate of infusion has exceeded 100mg/min. As part of the dose-escalation design, the investigators will start with 5mg/kg, half the smallest described dose, on a sample of up to 5 women. They will continue to administer TxA doses in increments of 5mg/kg to each successive batch of 5 women. If the number of treatment successes cannot statistically rule out a value < 75% (< 4 of 5 women are successes due to values in the low range), the dose will be increased by 5mg/kg for the next set of 5 women, and so on, until a maximum dose of 30mg/kg is reached, a dose deemed safe based on earlier studies in different populations. Once treatment success is determined at a certain dose, i.e. 4/5 women have levels in the therapeutic range), a total of 20 women will be administered that dose to ensure that 75% i.e. 18/20 women are successes at that dose.

NCT ID: NCT03463993 Recruiting - Clinical trials for Post Partum Hemorrhage

Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section

Start date: April 8, 2018
Phase: Phase 3
Study type: Interventional

Background Postpartum haemorrhage (PPH) is a major cause of maternal mortality worldwide accounting for 25% of maternal deaths. In Zimbabwe PPH is the second most common cause of death. Tranexamic acid (TXA) is widely used to reduce blood loss in elective surgery, bleeding trauma patients, and menorrhagia. The investigators seek to determine the efficacy of TXA in reducing PPH during and after elective caesarean section. Methods and Design The investigators intend to perform an open label randomized control study of 1,162 women who are undergoing elective caesarean section. The participants will be randomly selected to receive an intravenous infusion of TXA 10 minutes prior to skin incision or not to receive the intervention. Prophylactic oxytocin will be administered to all the women. The primary outcome will be incidence of PPH defined by blood loss equal to or more than 1,000ml calculated by determining the difference in haematocrit values taken prior to and 48 hours after caesarean section. Discussion In addition to prophylactic uterotonic administration, TXA is a complementary component acting on the haemostatic process that can be used in the third stage of labour to prevent PPH. It is a promising intervention that is cheap, easy to administer and would be easy to add to routine delivery protocols in hospitals. It would also help to conserve precious resources by reducing the need for blood products, and expensive surgical interventions to manage PPH. This large adequately powered randomized study seeks to determine the efficacy of TXA to validate its routine use at caesarean section to prevent PPH.

NCT ID: NCT03463070 Not yet recruiting - Clinical trials for Post Partum Hemorrhage

Misoprostol Before and After Cesarean Section

Start date: March 2018
Phase: Phase 3
Study type: Interventional

comparison of the effect of misoprostol before and after cesarean on the blood loss

NCT ID: NCT03449420 Completed - Clinical trials for Post Partum Hemorrhage

Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage

Start date: January 2012
Phase: N/A
Study type: Observational

The aim of the study is to determine if thromboelastography parameters can be predictive of severe post partum hemorrhage.